Stockscreener 앱 받기
18.02
7.84%
1.31
시간 외 거래:
17.95
-0.07
-0.39%
전일 마감가:
$16.71
열려 있는:
$16.93
하루 거래량:
707.78K
Relative Volume:
0.38
시가총액:
$1.29B
수익:
-
순이익/손실:
$-230.32M
주가수익비율:
-5.1108
EPS:
-3.5259
순현금흐름:
$-196.04M
1주 성능:
+11.03%
1개월 성능:
-1.10%
6개월 성능:
-68.04%
1년 성능:
-54.58%
1일 변동 폭
$16.88
$18.03
1주일 범위
$16.03
$18.03
52주 변동 폭
$5.95
$62.75
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Company Profile
명칭
Moonlake Immunotherapeutics
전화
41 41 510 8022
주소
DORFSTRASSE 29, ZUG
Compare MLTX vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
18.02 | 1.20B | 0 | -230.32M | -196.04M | -3.5259 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-19 | 업그레이드 | Rothschild & Co Redburn | Neutral → Buy |
| 2026-01-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2026-01-09 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2025-11-03 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-10-02 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-09-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-09-30 | 다운그레이드 | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-09-29 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-09-29 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-07-28 | 개시 | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-17 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-11-05 | 재개 | Wedbush | Outperform |
| 2024-08-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-04-02 | 개시 | Goldman | Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-08 | 개시 | Citigroup | Buy |
| 2023-11-02 | 개시 | Stifel | Buy |
| 2023-09-14 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | 개시 | Needham | Buy |
| 2023-06-15 | 개시 | Barclays | Equal Weight |
| 2023-05-01 | 개시 | Guggenheim | Buy |
| 2023-03-22 | 개시 | Wedbush | Outperform |
| 2023-03-09 | 개시 | BTIG Research | Buy |
| 2023-02-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-02 | 개시 | Bryan Garnier | Buy |
| 2022-11-11 | 개시 | Jefferies | Buy |
| 2022-08-25 | 개시 | SVB Leerink | Outperform |
| 2022-07-21 | 개시 | H.C. Wainwright | Buy |
| 2022-07-07 | 개시 | Cowen | Outperform |
모두보기
문레이크 이뮤노테라퓨틱스 주식(MLTX)의 최신 뉴스
Breakout Watch: What is the Moat Score of MoonLake Immunotherapeutics2026 Action & Fast Gaining Stock Reports - baoquankhu1.vn
MoonLake stock soars as biotech fund reloads, takeover chatter ignites - MSN
MoonLake surges 65% after InvestingPro Fair Value identifies opportunity By Investing.com - Investing.com Australia
Wolfe Research upgrades Moonlake stock rating on positive 2026 outlook By Investing.com - Investing.com India
MoonLake upgraded to Outperform from Underperform at Wolfe Research - TipRanks
HLXC,MLTX Volatility & Greeks - Finviz
MLTX Upgraded to 'Outperform' by Wolfe Research with Target Pric - GuruFocus
HLXC,MLTX Forecast, Target Price - Finviz
This APA Analyst Is No Longer Bearish; Here Are Top 2 Upgrades For Monday - Benzinga
Wolfe Research Upgrades MoonLake Immunotherapeutics(MLTX.US) to Buy Rating, Announces Target Price $24 - 富途牛牛
Wolfe Research Upgrades MoonLake Immunotherapeutics (NASDAQ:MLTX) to "Outperform" - MarketBeat
Wolfe Research upgrades Moonlake stock rating on positive 2026 outlook - Investing.com
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? - AOL.com
MoonLake upgraded at Rothschild & Co Redburn citing potential FDA nod for lead drug - MSN
MoonLake cut to sell at Goldman Sachs on risks to lead asset’s approval - MSN
Citi Maintains MoonLake Immunotherapeutics(MLTX.US) With Sell Rating, Maintains Target Price $6 - 富途牛牛
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Cormorant’s Large Share Purchase - simplywall.st
Technical Reactions to MLTX Trends in Macro Strategies - Stock Traders Daily
MLTX Stock Chart | MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ:MLTX) - ChartMill
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up After Analyst Upgrade - MarketBeat
Rothschild & Co Redburn Upgrades MoonLake Immunotherapeutics(MLTX.US) to Buy Rating, Cuts Target Price to $40 - 富途牛牛
MoonLake Immunotherapeutics (NASDAQ:MLTX) Upgraded by Rothschild & Co Redburn to Buy Rating - MarketBeat
MoonLake upgraded to Buy from Neutral at Rothschild & Co Redburn - TipRanks
Rothschild Redburn upgrades Moonlake stock on regulatory clarity - Investing.com
Rothschild & Co upgrades MoonLake Immunotherapeutics (MLTX) - MSN
MoonLake Immunotherapeutics (MLTX) price target increased by 11.25% to 22.30 - MSN
Caitong International Asset Management Co. Ltd Increases Holdings in MoonLake Immunotherapeutics $MLTX - MarketBeat
Earnings Beat: Will MoonLake Immunotherapeutics be affected by tariffs2026 EndofYear Setup & Entry Point Confirmation Signals - baoquankhu1.vn
RBC Capital Downgrades MoonLake Immunotherapeutics (MLTX) - MSN
This fund acquired $28 million worth of a struggling immunotherapy stock last quarter. What important information should long-term investors consider? - Bitget
Boxer Capital Management LLC Acquires New Holdings in MoonLake Immunotherapeutics $MLTX - MarketBeat
Avoro Capital Advisors LLC Cuts Stock Position in MoonLake Immunotherapeutics $MLTX - MarketBeat
TD Cowen Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating - 富途牛牛
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
MLTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (MLTX), Sarepta Therapeutics (SRPT) and vTv Therapeutics (VTVT) - The Globe and Mail
Clear Street Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $70 - 富途牛牛
Clear Street raises Moonlake stock price target on IL-17 data - Investing.com Nigeria
MoonLake price target raised to $70 from $45 at Clear Street - TipRanks
Clear Street raises Moonlake stock price target on IL-17 data By Investing.com - Investing.com Australia
How Investors Are Reacting To MoonLake Immunotherapeutics (MLTX) Widening Annual Net Loss Amid Share Price Gains - simplywall.st
Trading the Move, Not the Narrative: (MLTX) Edition - Stock Traders Daily
Rhenman & Partners Asset Management AB Buys 162,000 Shares of MoonLake Immunotherapeutics $MLTX - MarketBeat
MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout - MSN
문레이크 이뮤노테라퓨틱스 (MLTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):